School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

CITIUS ONCOLOGY, INC. CTOR

Healthcare · Drug Manufacturers - Specialty & Generic

$0.84last close 2026-10-09 · market cap $88.82M · delayed data

Trailing returns

1M-10.64%
3M+16.50%
6M+27.27%
1Y-54.10%

Basis: Adjusted daily closes.

What it does

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc.

Open CTOR in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies